Search results
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
The team have found the cause of disease in the first ever family tree drawn up at Moorfields Eye Hospital over 35 years ago, which had remained unsolved until now.
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
Introducing Splice Bio, a genetic medicines company with some exciting developments for Stargardt’s patients.
Hajrah Sarkar is a PhD student whose project is funded by Retina UK.
Nurturing a new generation of scientists is a vital investment in the future of retinal disease research, so we are delighted to be funding, in collaboration with the Macular Society, a new PhD studentship at Oxford University, supervised by Professor Robert MacLaren.
The BBC covered a story on Monday 24 May about optogenetics partially restoring the sight of a man living with retinitis pigmentosa in France.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
This edition marks the start of the charity's 50th anniversary year. It includes lots of ways to get involved over the next 12 months along with details of our Annual and Professionals' Conferences in September.
